| Mrs Alimatu Kosnatu Nabie, CRNP | |
|
5401 Old Court Rd, Randallstown, MD 21133-5103 | |
| (410) 521-2200 | |
| Not Available |
| Full Name | Mrs Alimatu Kosnatu Nabie |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 7 Years |
| Location | 5401 Old Court Rd, Randallstown, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053820621 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LP0808X | Nurse Practitioner - Psychiatric/mental Health | R193770 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vesta, Inc. | 3678568375 | 22 |
| Arundel Mental Health Professionals Lc | 4981688173 | 45 |
| Vesta, Inc. | 3678568375 | 22 |
News Archive
Unilife Medical Solutions Limited today announced the filing of patent applications in the United States ("US") for a new ready-to-fill syringe product to be marketed as the Unifill™ Select. Unilife is confident that this new pipeline product, which is to be primarily targeted for use with vaccines, can further expand the Company's ability to penetrate the pharmaceutical market for prefilled syringes.
Inflammatory bowel disease (IBD), of which Crohn's disease and ulcerative colitis are the main types, is on the increase in the United States, affecting more than 1.6 million people and explaining perhaps the increase in advertisements offering treatments and cures.
Using a non-invasive imaging technique that measures the stiffness of tissues gives crucial new information about cancer architecture and could aid the delivery of treatment to the most challenging tumors, new research shows.
A team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB) therapies in preventing disease progression among patients with mild to moderate COVID-19. The findings reveal that the timing of initiating MAB therapy is a crucial factor in determining its efficacy against COVID-19.
› Verified 5 days ago
| Entity Name | Arundel Mental Health Professionals Lc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073649521 PECOS PAC ID: 4981688173 Enrollment ID: O20040615001556 |
News Archive
Unilife Medical Solutions Limited today announced the filing of patent applications in the United States ("US") for a new ready-to-fill syringe product to be marketed as the Unifill™ Select. Unilife is confident that this new pipeline product, which is to be primarily targeted for use with vaccines, can further expand the Company's ability to penetrate the pharmaceutical market for prefilled syringes.
Inflammatory bowel disease (IBD), of which Crohn's disease and ulcerative colitis are the main types, is on the increase in the United States, affecting more than 1.6 million people and explaining perhaps the increase in advertisements offering treatments and cures.
Using a non-invasive imaging technique that measures the stiffness of tissues gives crucial new information about cancer architecture and could aid the delivery of treatment to the most challenging tumors, new research shows.
A team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB) therapies in preventing disease progression among patients with mild to moderate COVID-19. The findings reveal that the timing of initiating MAB therapy is a crucial factor in determining its efficacy against COVID-19.
› Verified 5 days ago
| Entity Name | Vesta, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790995017 PECOS PAC ID: 3678568375 Enrollment ID: O20050411001119 |
News Archive
Unilife Medical Solutions Limited today announced the filing of patent applications in the United States ("US") for a new ready-to-fill syringe product to be marketed as the Unifill™ Select. Unilife is confident that this new pipeline product, which is to be primarily targeted for use with vaccines, can further expand the Company's ability to penetrate the pharmaceutical market for prefilled syringes.
Inflammatory bowel disease (IBD), of which Crohn's disease and ulcerative colitis are the main types, is on the increase in the United States, affecting more than 1.6 million people and explaining perhaps the increase in advertisements offering treatments and cures.
Using a non-invasive imaging technique that measures the stiffness of tissues gives crucial new information about cancer architecture and could aid the delivery of treatment to the most challenging tumors, new research shows.
A team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB) therapies in preventing disease progression among patients with mild to moderate COVID-19. The findings reveal that the timing of initiating MAB therapy is a crucial factor in determining its efficacy against COVID-19.
› Verified 5 days ago
| Entity Name | Windrush Behavioral Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124404421 PECOS PAC ID: 5890002224 Enrollment ID: O20150917002164 |
News Archive
Unilife Medical Solutions Limited today announced the filing of patent applications in the United States ("US") for a new ready-to-fill syringe product to be marketed as the Unifill™ Select. Unilife is confident that this new pipeline product, which is to be primarily targeted for use with vaccines, can further expand the Company's ability to penetrate the pharmaceutical market for prefilled syringes.
Inflammatory bowel disease (IBD), of which Crohn's disease and ulcerative colitis are the main types, is on the increase in the United States, affecting more than 1.6 million people and explaining perhaps the increase in advertisements offering treatments and cures.
Using a non-invasive imaging technique that measures the stiffness of tissues gives crucial new information about cancer architecture and could aid the delivery of treatment to the most challenging tumors, new research shows.
A team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB) therapies in preventing disease progression among patients with mild to moderate COVID-19. The findings reveal that the timing of initiating MAB therapy is a crucial factor in determining its efficacy against COVID-19.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Alimatu Kosnatu Nabie, CRNP 30 Cinnabar Ct, Gaithersburg, MD 20879-4570 Ph: (717) 645-0762 | Mrs Alimatu Kosnatu Nabie, CRNP 5401 Old Court Rd, Randallstown, MD 21133-5103 Ph: (410) 521-2200 |
News Archive
Unilife Medical Solutions Limited today announced the filing of patent applications in the United States ("US") for a new ready-to-fill syringe product to be marketed as the Unifill™ Select. Unilife is confident that this new pipeline product, which is to be primarily targeted for use with vaccines, can further expand the Company's ability to penetrate the pharmaceutical market for prefilled syringes.
Inflammatory bowel disease (IBD), of which Crohn's disease and ulcerative colitis are the main types, is on the increase in the United States, affecting more than 1.6 million people and explaining perhaps the increase in advertisements offering treatments and cures.
Using a non-invasive imaging technique that measures the stiffness of tissues gives crucial new information about cancer architecture and could aid the delivery of treatment to the most challenging tumors, new research shows.
A team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB) therapies in preventing disease progression among patients with mild to moderate COVID-19. The findings reveal that the timing of initiating MAB therapy is a crucial factor in determining its efficacy against COVID-19.
› Verified 5 days ago
Margaret Mensa, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 25 Adrianne Ct, Randallstown, Randallstown, MD 21133 Phone: 410-655-6105 | |
Devorah Howell, ACNP-AG Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 5401 Old Court Rd, Randallstown, MD 21133 Phone: 410-521-2200 | |
Bilikisu Adekanbi, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3805 Kilburn Rd, Randallstown, MD 21133 Phone: 646-318-4816 | |
Dr. Amelia Oretha Saydee, DNP, FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 9100 Meadow Heights Rd, Randallstown, MD 21133 Phone: 443-857-5012 | |
Happiness Nwosu, CRNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 8933 Greens Ln, Randallstown, MD 21133 Phone: 443-632-7398 | |
Nelly Enone, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 9429 Silver Charm Dr, Randallstown, MD 21133 Phone: 410-493-3070 |